Nanoparticulate systems for polynucleotide delivery by Basarkar, Ashwin & Singh, Jagdish
© 2007 Dove Medical Press Limited.   All rights reserved
International Journal of Nanomedicine 2007:2(3) 353–360 353
REVIEW
Nanoparticulate systems for polynucleotide 
delivery
Ashwin Basarkar
Jagdish Singh
Department of Pharmaceutical 
Sciences, College of Pharmacy, 
Nursing, and Allied Sciences, North 
Dakota State University, Fargo, ND, 
USA
Correspondence: Jagdish Singh
Department of Pharmaceutical Sciences, 
College of Pharmacy, Nursing, and Allied 
Sciences, North Dakota State University, 
Fargo, ND 58105, USA
Tel +1 701 231 7943
Fax +1 701 231 8333
Email jagdish.singh@ndsu.edu
Abstract: Nanotechnology has tremendously influenced gene therapy research in recent 
years. Nanometer-size systems have been extensively investigated for delivering genes 
at both local and systemic levels. These systems offer several advantages in terms of 
tissue penetrability, cellular uptake, systemic circulation, and cell targeting as compared 
to larger systems. They can protect the polynucleotide from a variety of degradative and 
destabilizing factors and enhance delivery efficiency to the cells. A variety of polymeric 
and non-polymeric nanoparticles have been investigated in an effort to maximize the 
delivery efficiency while minimizing the toxic effects. This article provides a review on 
the most commonly used nanoparticulate systems for gene delivery. We have discussed 
frequently used polymers, such as, polyethyleneimine, poly (lactide-co-glycolide), chitosan, 
as well as non-polymeric materials such as cationic lipids and metallic nanoparticles. The 
advantages and limitations of each system have been elaborated.
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Introduction
The ﬁ  eld of gene-based medicine has witnessed great progress since the ﬁ  rst somatic gene 
therapy performed in 1990. Several thousand patients have been involved in clinical trials 
all over the world with majority focusing on cancer (67%), followed by vascular diseases 
(8.9%) and monogenic diseases (8.6%) (http://www.wiley.co.uk/genetherapy/clinical). 
Gene therapy works on the basic concept that the delivery of polynucleotides to the cells 
will alter the expression of a given protein resulting in therapeutic beneﬁ  t. Gene therapy 
involves delivering polynucleotides such as DNA, RNA, anti-sense oligonucleotides and 
small interfering RNA, either locally or systemically. Although Vitravene, an antisense 
oligonucleotide-based product, is the only gene delivery product approved so far by 
US-FDA, there are several other products in late stages of clinical trials. Gendicine, 
an adenovirus encoding tumor suppressor p53 gene, developed by SiBiono GeneTech 
Co., Ltd., was recently approved by China’s state food and drug administration, for the 
treatment of head and neck squamous cell carcinoma.
Delivering functional polynucleotides into cells is the ﬁ  rst and most critical step 
towards efﬁ  cient gene therapy. The administration of naked DNA resulted in local 
transient expression in skeletal muscle tissue (Wolff et al 1990). Efﬁ  cient transfec-
tion levels have also been obtained on direct application of naked DNA to the liver 
(Hickman et al 1994). To obtain systemic effect with the injection of naked DNA is 
difﬁ  cult, however, as the intravenous injection of naked DNA results in low levels of 
gene expression in all major organs.
In order to enhance uptake of genes into cells, they have to be delivered 
using a carriers or vectors. The vectors can be broadly classified as viral and 
non-viral. Viral vectors account for nearly 75% of all clinical trials conducted International Journal of Nanomedicine 2007:2(3) 354
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so far (http://www.wiley.co.uk/genetherapy/clinical). 
They are essentially viruses that have been stripped of 
their gene for replication while preserving their ability to 
transfect cells. The gene of interest is then incorporated 
into the viral genome. Most commonly used viral vectors 
are retrovirus, adenovirus, adeno-associated virus and 
herpes simplex virus (Robbins and Ghivizzani 1998; Wal-
ther and Stein 2000)). Virus based approaches are highly 
efficient as viruses have a highly evolved and specific 
mechanism for inserting their genome into that of host 
cell. Despite the high efficiency of viral vectors, their use 
has been limited by their pathogenicity, immunogenicity 
and potential for insertional mutagenesis.
Incidences of severe adverse reactions using viral 
vectors during clinical trials have caused a gradual shift 
towards non-viral vectors. Non-viral vectors mostly 
include use of polymers and lipids to deliver genetic ma-
terial intracellularly protecting it from extracellular and 
intracellular degradative enzymes and blood components 
(De Laporte et al 2006). Non-viral vectors are mostly 
non-immunogenic, less expensive to produce, relatively 
safer, and can carry higher amounts of genetic material 
as compared to viruses. However, transfection efficiency 
using non-viral vectors remains lower as compared to 
viral vectors.
Challenges associated with non-viral 
gene delivery
Non-viral vectors face a multitude of barriers at systemic, 
tissue and cellular levels that prevent efﬁ  cient gene delivery 
to the nucleus of cells. A signiﬁ  cant portion of DNA is lost 
at each step, resulting in a several fold decrease in expres-
sion of the encoded protein. Most non-viral delivery vectors 
display colloidal instability which results in aggregation of 
the complexes thereby hindering cellular internalization. 
Systemic delivery of charged vector may result in interac-
tion with blood components which may lead to opsonisation 
by the reticulo-endothelial system (Liu and Huang 2002). 
Problems such as steric instability and rapid plasma clear-
ance have been partly overcome by shielding the surface 
charge of the vectors (Kommareddy et al 2005). Properties 
of vector such as size, shape, and surface characteristics can 
also have a major impact on its pharmacokinetic properties 
and delivery efﬁ  ciency.
Non-viral vectors, also encounter several extracellular 
and intracellular barriers before reaching its ﬁ  nal destination, 
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Figure 1 Schematic diagram of the entry of non-viral vector inside the nucleus of cell.International Journal of Nanomedicine 2007:2(3) 355
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the nucleus (Ruponen et al 2003; Wiethoff and Middaugh 
2003). Typical pathway of a nanoparticulate vector inside the 
cell is depicted in Figure 1. The presence of nucleases in the 
extracellular compartment may lead to extensive degradation 
of the DNA. Cellular internalization is another major barrier 
as DNA is a polyanionic molecule with a large hydrodynamic 
volume which makes its entry through the negatively charged 
plasma membrane extremely difﬁ  cult. Following uptake into 
the cell, the vector may become trapped within the endosomal 
compartment, from which it must escape. Failure to do so 
may result in degradation of DNA by lysosomal degradative 
enzymes. Surviving passage through the cytoplasm is a cru-
cial step, because of the presence of cytosolic endonucleases, 
which may further lead to DNA fragmentation. Lastly, the 
DNA has to traverse the nuclear envelope to get transcribed. 
In order to enhance gene therapy, specialized design features 
are required for delivery vector to overcome each of these 
barriers, and ensure efﬁ  cient DNA delivery to the nucleus.
Nanoparticulate vectors 
for polynucleotide delivery
Nanotechnology has been at the forefront of drug and gene 
delivery in the last few years. Several types of nanometer 
scale devices such as nanoparticles, nanospheres, nanotubes, 
nanogels and molecular conjugates are being investigated 
(Lemieux et al 2000; Bianco 2004; Ravi Kumar et al 2004; 
Heidel et al 2005; Murakami and Nakashima 2006). Sub-
micron size of delivery systems confers distinct advantages 
as compared to large sized systems such as higher and deeper 
tissue penetrability, greater cellular uptake, greater ability of 
cross blood-brain barrier, and greater ability to target speciﬁ  c 
cell types (Kreuter et al 1995; Davis 1997; Vinogradov et al 
2002; Vogt et al 2006). Although this review, for most part, 
deals with polymeric nanoparticles, commonly used non-
polymeric nanovectors have also been discussed brieﬂ  y. A 
summary of all the nanoparticulate vectors discussed in the 
review is presented in Table 1.
Polymeric nanoparticles
Polymeric nanoparticles or nanospheres are the most com-
monly used type of nano-scale delivery systems. They are 
mostly spherical particles, in the size range of 1–1000 nm, 
carrying the genetic material of interest. The mechanism of 
incorporation of polynucleotides into polymeric nanoparticles 
depends on the nature of the polymer. Most cationic polymers 
have the ability to condense plasmid DNA into nanometer 
size complexes (polyplexes). DNA can also be entrapped into 
the polymeric matrix or can be adsorbed or conjugated on the 
Table 1 Polymeric and non-polymeric nanoparticulate vectors for gene delivery
 Nanoparticles  Properties  References
  Poly lactide-co-glycolide (PLGA) and  Biocompatible and biodegradable, can provide   Kim et al 2005; 
  Poly lactic acid (PLA)  sustained delivery of polynucleotides.   Ribiero et al 2005
  Polyethyleneimine (PEI)  High transfection efﬁ  ciency owing to faster   Moghimi et al 
    endosomal escape. High toxicity reported in vitro   2005; Thomas et al
    and in vivo.  2005 
  Polymethacrylate  Lower toxicity as compared to PEI. Endosomal   Dubruel et al 
Polymeric    buffering ability similar to PEI.  2003; Feng et al 
     2006
  Poly-L-Lysine (PLL)  Biodegradable. Slow endosomal escape resulting   Merdan et al 
    in lower transfection efﬁ  ciency  2002; Zhang et al 
     2004
 Poly  (β-amino ester) (PBAE)  High transfection efﬁ  ciency comparable to PEI.   Lynn and Langer 
    Prolonged release of polynucleotide.   2000; Little et al 
     2005
  Chitosan  Mucoadhesive property desired for oral and nasal   Ferrari et al 1997;
    delivery. Slow onset of expression.   Koping-Hoggard 
      et al 2001
  Cationic liposomes  Extensively used for in vitro transfections. High   Felgner et al 
    in vivo toxicity  1987; Tousignant 
      et al 2000
Non-polymeric  Gold Nanoparticles  Highly inert and non-toxic. Surface   Kawano et al al 
    functionalization can be easily performed.  2006; Sandhu et al
     2002
  Magnetic nanoparticles  High transfection efﬁ  ciency in variety of cell   Huth et al 2004; 
    lines.   Scherer et al 2002International Journal of Nanomedicine 2007:2(3) 356
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surface of nanoparticles. A variety of natural and synthetic 
polymers have been used for gene delivery. In this section, 
we have discussed the most extensively used polymers for 
nanoparticle-based gene delivery.
Poly lactide-co-glycolide (PLGA) and Poly lactic acid 
(PLA)
Biodegradable polyesters, PLGA and PLA are amongst 
the most commonly used polymers for delivering drugs 
and biomolecules. They consist of units of lactic acid and 
glycolic acid connected through ester linkage. These biode-
gradable polymers undergo bulk hydrolysis thereby provid-
ing sustained delivery of the therapeutic agent. The rate of 
degradation of polymer, and the release rate of drug, can be 
controlled by changing the polymer molecular weight and 
copolymer composition. The degradation products, lactic 
acid and glycolic acid, are removed from the body through 
citric acid cycle (Shive and Anderson 1997). The release of 
therapeutic agent from these polymers occurs by diffusion 
and polymer degradation.
PLGA and PLA nanoparticles are mostly matrix-type 
systems prepared by emulsiﬁ  cation followed by evaporation 
of the organic phase (Rosca et al 2004). Several studies have 
shown higher uptake of nanoparticles into cells as compared 
to larger size particles (Desai et al 1996; Desai et al 1997; 
Delie et al 2001; Panyam et al 2002). Nanoparticles have the 
ability to escape endo-lysosomal compartments and release 
the therapeutic molecule inside the cell at a sustained rate 
(Panyam et al 2002; Kim and Martin 2006). The release pat-
tern can be modulated according to the dosing requirement 
by changing various formulation parameters. The poly-
nucleotide can be incorporated in PLGA/PLA nanoparticles 
by either entrapment into the polymeric matrix (Ribeiro et al 
2005) or by surface-adsorption by using a cationic polymer 
or surfactant (Kim et al 2005). PLGA and PLA nanoparticles 
have been used for the delivering plasmid DNA (Cohen 
et al 2000), siRNA (Yuan et al 2006), and aptamers (Cheng 
et al 2007).
Cationic polymers
Cationic polymers by virtue of their positive charge can 
efﬁ  ciently condense the anionic polynucleotides into nano-
meter range complexes (polyplexes) thereby masking their 
negative charge (De Smedt et al 2000; Zhang et al 2004). 
Polynucleotides are polyanionic molecules with a large 
hydrodynamic diameter which presents a signiﬁ  cant bar-
rier towards efﬁ  cient cellular uptake. Cationic polymers, 
apart from condensing it to a several fold smaller size, also 
provide a net positive charge to the complex which helps 
in attachment on cellular membrane. Also, most cationic 
polymers bear amine groups that are protonable at acidic 
pH. Thus, once inside the endosome, these polymers accept 
proton thereby resisting a drop in pH. This causes inﬂ  ux of 
counterions (chloride ions) resulting in osmotic swelling 
and subsequent rupture of endosome. This phenomenon, 
ﬁ  rst explained by Behr, is known as proton sponge effect 
(Behr 1997). The efﬁ  ciency of polyplexes has been found to 
be dependent on the ratio of nitrogen atoms of the polymer 
to the phosphate groups present in the polynucleotide (N/P 
ratio) (Gebhart and Kabanov 2001). A variety of natural and 
synthetic cationic polymers have been used for gene delivery. 
Some of the most commonly used cationic polymers have 
been discussed below.
Polyethylenimine (PEI)
Polyethyleneimine is the most commonly used cat-
ionic polymer and is widely regarded as a gold standard, 
amongst non-viral vectors, in order to compare transfection 
efﬁ  ciencies. Transfection efﬁ  ciency of PEI has been found 
to be dependent on a multitude of factors such as molecular 
weight, degree of branching, N/P ratio, complex size etc 
(Thomas et al 2005). PEI has a high density of protonable 
amino groups, every third atom being amino nitrogen, 
which imparts it a high buffering ability at practically any 
pH. Hence, once inside the endolysosomal compartment, 
PEI can efﬁ  ciently destabilize the endosome releasing the 
polynucleotide in the cytoplasm. PEI can also be used in 
combination with PLGA/PLA for preparing matrix-type 
nanoparticles to deliver DNA by adsorption/complexation 
on the surface (Kim et al 2005). Toxicity of PEI, however, 
has been a concern. Acute toxicity has been observed in 
several studies both in vitro and in vivo (Chollet et al 2002; 
Moghimi et al 2005). Investigators have studied conjuga-
tion of polyethylene glycol (PEG) to PEI to form diblock 
or triblock copolymers to reduce PEI-associated toxicity 
(Park et al 2005; Zhong et al 2005; Choi et al 2006). PEG 
also shields the positive charge of the polyplexes, thereby 
providing steric stability to the complex. Such stabilization 
prevents non-speciﬁ  c interaction with blood components 
during systemic delivery (Kursa et al 2003).
Polymethacrylates
Polymethacrylates are cationic vinyl-based polymers that 
possess the ability to condense polynucleotides into nano-
meter size particles. Several polymethacrylates such as 
poly [2-(dimethylamino) ethyl methacrylate] (DMAEMA) International Journal of Nanomedicine 2007:2(3) 357
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and its co-polymers have been used for polynucleotide 
delivery. Presence of protonable tertiary amine groups in 
their structure provides buffering ability similar to that of 
PEI. A range of Polymethacrylates, differing in molecular 
weights and chemical structures, have been evaluated for 
their potential as gene delivery vector (Dubruel et al 2003; 
Dubruel et al 2004). Polymethacrylates containing only 
tertiary amine groups were found to be similar to PEI in 
terms of transfection efﬁ  ciency while displaying much better 
biocompatibility proﬁ  le (Dubruel et al 2004). Nanoparticles 
with a methacrylate core and PEI shell prepared via graft 
copolymerization have also been employed lately for gene 
delivery (Li et al 2002; Feng et al 2006). Such conjugation 
resulted in nanoparticles with a higher transfection efﬁ  ciency 
and lower toxicity as compared to PEI alone. We have re-
cently formulated cationic nanoparticles with commercially 
available polymethacrylate Eudragit® E100 in combination 
with PLGA/PLA using cationic surfactant, cetyltrimethyl-
ammonium bromide (CTAB), and achieved much improved 
transfection efﬁ  ciency as compared to PLA/CTAB and 
PLGA/CTAB nanoparticles (Unpublished data).
Poly-L-Lysine (PLL)
Poly-l-lysine is amongst the ﬁ  rst cationic polymers investigat-
ed for gene delivery. It is a biodegradable polymer synthesized 
by polymerization of N-carboxy-anhydride of lysine (Zhang 
et al 2004). Biodegradability is a highly desirable property 
for gene delivery applications in vivo. Poly-l-lysine is able to 
form nanometer size complexes with polynucleotides owing 
to the presence of protonable amine groups on the lysine 
moiety. Complexation of PLL with polynucleotide results 
in formation of toroidal or rod-shaped polyplexes less than 
100 nm in size (Kwoh et al 1999). Although PLL polyplexes 
have shown good cellular uptake, their transfection efﬁ  ciency 
is several folds lower than PEI polyplexes (Merdan et al 2002). 
Possible reason for this may be reduced endosomal escape due 
to lack of amine groups that can be protonated at acidic pH 
(Akinc and Langer 2002). Resultant lack of buffering ability 
leads to degradation of polyplexes by lysosomal enzymes. 
Conjugation of PLL with poly (ethylene glycol (PEG) has been 
performed to shield charge on the surface thereby providing in 
vivo stability, delaying body clearance, and protecting DNA 
from nuclease degradation (Katayose et al 1998; Kwoh et al 
1999). Enhanced transfection efﬁ  ciency has been observed by 
conjugating the PLL polyplexes with membrane disruptive 
peptides and fusion peptides (Wagner et al 1992; Lee et al 
2002). Delivery of siRNA using PLL has also been reported 
(Moriguchi et al 2005).
Poly (β-amino ester)s
Poly (β-amino ester) (PBAE) is a novel, charge inducible, 
biodegradable, and non-toxic polymer. PBAE polyplexes 
have been prepared and optimized in terms of polymer 
molecular weight, polymer end groups, complex size, and 
DNA/polymer ratio (Lynn and Langer 2000; Akinc et al 
2003). The polyplexes displayed transfection efﬁ  ciencies 
comparable to PEI and commercial lipid-based transfection 
reagents and were able to transfect a variety of cell types 
(Akinc et al 2003). The complexes displayed signiﬁ  cantly 
low cytotoxicity as compared to PEI polyplexes in vitro 
(Lynn and Langer 2000). PBAE in combination with PLGA 
was used for DNA vaccination and led to signiﬁ  cant enhance-
ment in transfection efﬁ  ciency (Little et al 2004; Little et al 
2005). PBAE/PLGA microparticles showed high immuno-
genic potential and led to a signiﬁ  cant reduction of tumor size 
in mice (Little et al 2004). PBAE/PLGA particles were also 
able to delay the release of plasmid DNA for several days 
similar to PLGA particles thereby prolonging bioavailability 
(Little et al 2005).
Chitosan
Chitosan, a naturally derived polycation, is amongst most 
widely investigated polymers for gene delivery. Mucoadhe-
sive property of Chitosan makes it suitable for oral and nasal 
delivery of DNA (Ferrari et al 1997). Chitosan can deliver 
polynucleotides, both, by encapsulation and by complexation, 
forming positively charged particles (Bozkir and Saka 2004a; 
Koping-Hoggard et al 2004). Chitosan nanoparticles efﬁ  ciently 
protect DNA from nuclease degradation (Bozkir and Saka 
2004b). Chitosan nanoparticles have also been evaluated for 
siRNA delivery (Howard et al 2006; Katas and Alpar 2006). 
Transfection efﬁ  ciency of chitosan polyplexes is found to be 
dependent on charge ratio, pH, cell type, molecular weight of 
chitosan, and degree of deacetylation (Sato et al 2001; Koping-
Hoggard et al 2004; Lavertu et al 2006). Transfection efﬁ  -
ciency of optimized chitosan polyplexes was similar to PEI but 
the onset of expression was found to be slower than PEI which 
may be due to slower endosomal escape of chitosan nanopar-
ticles (Koping-Hoggard et al 2001). Recently, oligosaccharides 
derived from chitosan were evaluated for gene delivery after 
conjugation with stearic acid (Hu et al 2006). These nanopar-
ticles displayed transfection efﬁ  ciency comparable to that 
of commercial transfection reagent, LipofectamineTM 2000, 
at higher time points post-transfection, while showing low 
cytotoxicity. Chitosan polyplexes physically combined with 
PLGA microparticles have also been evaluated for sustained 
gene delivery (Yun et al 2005).International Journal of Nanomedicine 2007:2(3) 358
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Cationic liposomes
Liposomes are spherical vesicles made of phospholipids used 
to deliver drugs or genes inside the cells. They can range 
in size from 20 nm to a few microns. The use of cationic 
liposomes to deliver DNA into cells was ﬁ  rst reported in 
1987 (Felgner et al 1987). Since then, liposomes have been 
routinely used in gene delivery research. Positively charged 
liposomes combine with negatively charged polynucleotides 
to form liposome/polynucleotide complexes (lipoplexes). 
Although the positive charge of liposomes is a requirement 
for preparing lipoplexes, neutral lipids dioleoylphosphatidyl-
ethanolamine is also commonly incorporated. It facilitates 
endosomal destabilization apart from providing structural 
stability to the liposome. Liposomes destabilize the lipid 
bilayer membranes by promoting the formation of non-
bilayer lipid structures (Hafez et al 2001). Cellular entry of 
lipoplexes is shown to be primarily via clathrin-mediated 
endocytosis (Dass and Burton 2003). Liposomes have also 
been employed for cell-targeting using a variety of target-
ing ligands (Talsma et al 2006; Torchilin 2006). Although a 
variety of high-efﬁ  ciency liposomes are commercially avail-
able for transfecting cells in vitro and in vivo, their toxicity 
is still a concern. Several lipoplex formulations have caused 
moderate to severe toxicities in animal models (Stewart 
et al 1992; Tousignant et al 2000). At cellular level, lipo-
plexes have been reported to cause cell shrinking, reduced 
mitoses, and vacuolization of cytoplasm (Lappalainen et al 
1994).
Gold nanoparticles
Gold nanoparticles have lately been investigated as an 
alternative to lipid-mediated and polymer-mediated gene 
delivery. Gold nanoparticles can be easily prepared, display 
low toxicity, and the surface can be modiﬁ  ed using various 
chemical techniques. The gold nanoparticles functionalized 
using quarternary ammonium chains can efﬁ  ciently trans-
fect mammalian cells (Sandhu et al 2002). Up to 8 times 
higher transfection efﬁ  ciency compared to PEI was observed 
using optimized formulations. Systemic delivery of plasmid 
DNA using PEG-modiﬁ  ed gold nanoparticles resulted in 
improved stability and increased circulation time of DNA in 
the blood (Kawano et al 2006). Surface functionalization of 
gold nanoparticles using a PEG spacer also resulted in rapid 
cellular uptake and internalization (Shenoy et al 2006).
Magnetic nanoparticles
Delivery of polynucleotides using magnetic nanoparticles, 
also known as magnetofection, has been reported (Scherer 
et al 2002). In this technique, superparamagnetic iron oxide 
nanoparticles are prepared, and are coated with a polyelec-
trolyte such as PEI, to produce particles in size range of 400-
1000 nm. Surface coating of PEI facilitates complexation of 
DNA on the surface. These nanoparticles are then delivered to 
the cells under the inﬂ  uence of a magnetic ﬁ  eld. The mecha-
nism of cellular uptake of magnetofectins was shown to be 
analogous to PEI polyplexes (Huth et al 2004). Magnetofec-
tion for 10 minutes resulted in up to several hundred-fold 
increase in protein expression, compared to standard transfec-
tion, using a variety of transfection vectors in different cell 
lines (Scherer et al 2002). Another study reported an increase 
in transfection efﬁ  ciency in primary airway epithelial cells 
using megetofection (Gersting et al 2004).
A recent study, investigating non-viral gene transfer in vivo 
has, however, reported a decrease in transfection efﬁ  ciency 
using magnetic nanoparticles as compared to non-magnetic 
particles (Xenariou et al 2006). The versatility and potential 
applications of this technique thus remain to be seen.
Conclusions
The ultimate goal of gene therapy is to deliver genes with 
high transfection efﬁ  ciency to speciﬁ  c cells without causing 
any adverse effects. Viral vectors are efﬁ  cient at delivering 
genes but are inherently unsafe. Nanotechnology-based 
gene delivery vectors have shown tremendous potential 
at overcoming physiological and biochemical barriers 
towards efﬁ  cient gene delivery. Vector modiﬁ  cations at 
molecular level have enabled scientists to develop a variety 
of nanosystems with high efﬁ  ciency, high speciﬁ  city and 
low toxicity. With increase in the information available 
about cellular and molecular mechanisms involved in the 
uptake and transport of these carriers inside the cells, there 
is great hope for the future of nanoparticulate systems for 
gene delivery.
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